Gilead Sciences
Groundbreaking HIV Prevention: Biannual Lenacapavir Injections Launch in African Nations
Dec 01, 2025 09:50 pm CST
South Africa, Eswatini, and Zambia have begun administering lenacapavir, a revolutionary HIV prevention injection taken just twice yearly with 99.9% effectiveness. The rollout marks a significant advancement in HIV prevention across Africa, which bears the world's highest HIV burden. While initial distributions are limited, generic versions are expected by 2027 at approximately $40 annually, potentially transforming HIV prevention in regions where daily PrEP pills have shown limited impact.
HIV-Prevention Drug To Be Available For Rs 3,500 A Year From 2027
Sep 24, 2025 08:35 pm CST
Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 or Rs 3,548 a year in more than 100 countries from 2027, Unitaid and the Gates Foundation said Wednesday.